Cybin Inc. (NEO:CYBN)
Canada · Delayed Price · Currency is CAD | Market Cap | 195.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -131.93M |
| Shares Out | n/a |
| EPS (ttm) | -6.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,805 |
| Average Volume | 13,797 |
| Open | 8.65 |
| Previous Close | 8.43 |
| Day's Range | 8.12 - 8.65 |
| 52-Week Range | 6.95 - 19.46 |
| Beta | 1.11 |
| RSI | 37.75 |
| Earnings Date | Aug 11, 2025 |
About Cybin
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for M... [Read more]
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).
CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $CYBN--CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm.
Cybin to Participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing ...
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or the “Company”) (NYSE: CYBN). Such investors are advised to contact D...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN).
Cybin (CYBN) Completes Enrollment for Phase 2 Anxiety Disorder Study
Cybin (CYBN) Completes Enrollment for Phase 2 Anxiety Disorder Study
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized ...
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder | CYBN Stock News
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by d...
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
Cybin to Participate in the Cantor Global Healthcare Conference 2025
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
Cybin CEO steps down; co-founder named interim CEO
Cybin Announces Senior Leadership Changes
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healt...
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by d...
Cybin Announces Results of Annual Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by...
Cybin reports Q1 results
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental he...
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
– EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe, the United Kingdom, and Australia – –...
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by d...
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by d...
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental hea...
Cybin reports Q4 results
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental he...